Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

21. Donepezil for dementia in people with Down syndrome.

Donepezil for dementia in people with Down syndrome. BACKGROUND: Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome [DS]. Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Donepezil a reversible inhibitor of acetylcholinesterase, which is thought to maintain levels of acetylcholine, and is reported to have some benefits for people with AD in the general population. It is important to note (...) that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population. OBJECTIVES: To determine the effectiveness and safety of donepezil for people with DS who develop AD. SEARCH STRATEGY: CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted the manufacturers

Cochrane2009

22. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine (...) Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Rodda J, Morgan S, Walker Z CRD summary This review concluded that the evidence base regarding the efficacy of cholinesterase inhibitors for the behavioural and psychological symptoms of dementia was limited. The cautious conclusions reflected the evidence, but should

DARE.2009

23. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Lopez-Bastida J, Hart W, Garcia-Perez L, Linertova R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of treatment with donepezil for patients with mild or moderate Alzheimer's disease compared with no drug treatment. The authors concluded that donepezil was cost-effective for patients with mild Alzheimer's disease in Spain. The methods and reporting of the study were adequate and the authors’ conclusions appear

NHS Economic Evaluation Database.2009

24. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE CRD (...) summary This review concluded that cholinesterase inhibitors (donepezil, galantamine and rivastigmine) were able to stabilise or slow decline in cognition, function, behaviour and global change when compared with placebo. There was no clear evidence to determine whether one of these drugs was more efficacious than another. The review was generally well conducted and the conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety of cholinesterase inhibitors (donepezil

DARE.2008

26. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan

Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Fuh J L, Wang S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of donepezil compared with usual care for the treatment of patients with Alzheimer’s disease. The authors concluded that the use of donepezil in Taiwanese patients was potentially cost-effective, and was also cost-saving from a societal perspective. The study methodology seems robust but the sources used to populate the decision model were

NHS Economic Evaluation Database.2008

27. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review

The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review Ballesteros J, Guemes I, Ibarra N, Quemada JI CRD summary This review determined the effectiveness and safety of donepezil for cognitive rehabilitation after traumatic (...) brain injury and found significant evidence for a positive effect on general cognitive ability, short-term memory and attention. The authors' appropriately cautious conclusion was that the effectiveness and safety of donepezil were uncertain due to the limited evidence available. Authors' objectives To determine the effectiveness and safety of donepezil for cognitive rehabilitation after traumatic brain injury. Searching PubMed, PsycINFO and Cochrane Central Register of Controlled Trials (CENTRAL

DARE.2008

28. Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease

Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease Article Text Therapeutics Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Mental Health2008

29. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL 18296124 2008 03 14 2008 06 23 2014 08 15 1474-4422 7 4 2008 Apr The Lancet. Neurology Lancet Neurol Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. 310-8 10.1016/S1474-4422(08)70046-2 Cholinergic deficits might contribute to vascular cognitive impairment. Trials of cholinesterase inhibitors in patients with vascular (...) , randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL. 168 patients with CADASIL (mean age 54.8 years) were assigned to 10 mg donepezil per day (n=86) or placebo (n=82) by a computer-generated randomisation protocol. Inclusion criteria included a mini-mental state examination (MMSE) score of 10-27 or a trail making test (TMT) B time score at least 1.5 SD below the mean, after adjustment for age and education. The primary

EvidenceUpdates2008

30. Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long te

Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long te Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long term | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long term Article Text Therapeutics Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment

Evidence-Based Mental Health2007

31. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Weycker D, Taneja C, Edelsberg J, Erder M H, Schmitt F A, Setyawan J, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of adjuvant memantine in patients with moderate-to-severe Alzheimer’s disease, who were receiving stable doses of donepezil. The authors concluded that memantine plus donepezil improved the clinical outcomes and reduced the total costs of care

NHS Economic Evaluation Database.2007

32. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease

Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Teipel S J, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study determined the cost-effectiveness of donepezil, compared with current care (placebo), for the treatment of Alzheimer's disease in the German setting. The authors concluded that donepezil was a potentially cost-effective alternative to placebo, although the results were highly dependent on the assumptions about treatment effectiveness and remuneration of care-giving

NHS Economic Evaluation Database.2007

33. Donepezil orodispersible tablets (Aricept Evess)

Donepezil orodispersible tablets (Aricept Evess) Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: Rosie.Murray@nhshealthquality.org Chairman Professor David Webb donepezil 5mg and 10mg orodispersible tablets (Aricept® Evess) No. (307/06) Eisai Ltd Product Update 4 August 2006 (Issued February 2007) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area (...) Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission donepezil orodispersible tablet (Aricept Evess ® ) is accepted for use within NHS Scotland for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia in patients for whom donepezil is appropriate and who have difficulty in swallowing solid oral dose formulations. It costs the same as standard formulations of donepezil. Advice

Scottish Medicines Consortium2007

34. Donepezil for the treatment of agitation in Alzheimer's disease.

Donepezil for the treatment of agitation in Alzheimer's disease. 17914039 2007 10 04 2007 10 09 2016 12 03 1533-4406 357 14 2007 Oct 04 The New England journal of medicine N. Engl. J. Med. Donepezil for the treatment of agitation in Alzheimer's disease. 1382-92 Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear. We (...) randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks. There was no significant difference between the effects of donepezil and those

NEJM2007

35. Donepezil for mild cognitive impairment.

Donepezil for mild cognitive impairment. BACKGROUND: Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment (MCI), can be the first sign of an impending dementia, particularly Alzheimer's disease (AD). There is no consensus on a definition or diagnostic criteria for MCI, and MCI remains a vague term and those so described are a heterogeneous population, consisting of people who may rapidly progress to dementia but also of people (...) with stable cognitive deficits and some who may actually improve. Treatment in the very earliest stages of AD may delay progression to AD. Donepezil (Aricept, E2020), a cholinesterase inhibitor, has been shown to benefit all severities of AD including mild and it would be reasonable to investigate its efficacy for those with MCI. OBJECTIVES: To assess the effects of donepezil in people with mild cognitive impairment but no diagnosis of dementia. SEARCH STRATEGY: The trials were identified from a search

Cochrane2006

36. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2006

37. Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease

Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Article Text Therapeutics Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Free Krista L Lanctôt , PhD , Nathan

Evidence-Based Mental Health2006

38. Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease

Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease Article Text Therapeutics Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s

Evidence-Based Medicine (Requires free registration)2006

39. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment 2006; 10(1): 1-176 Authors' objectives The objective of this review was to provide an update review of the best quality evidence for the clinical effectiveness and cost

Health Technology Assessment (HTA) Database.2006

40. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 111. 2006 Authors' objectives This guidance constitutes a review of 'NICE technology appraisal guidance 19' on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately

Health Technology Assessment (HTA) Database.2006